10:24 AM EST - Satellos Bioscience Inc. : Today announced the publication in Nature Communications of new research from a scientific team at the Ottawa Hospital Research Institute (OHRI) that validates the company’s novel approach to treating the underlying cause of Duchenne muscular dystrophy and other diseases. Satellos Bioscience Inc.
shares T.MSCL are trading down $0.03 at $0.75.
